Article Information
History
- October 21, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Mark Redston, MD1,7,*,
- Amy Noffsinger, MD2,7,
- Anthony Kim, BS3,
- Fahire G Akarca, MD3,
- Diane Stapleton, MD2,
- Laurel Nowden, MD2,
- Richard Lash, MD4,
- Adam J Bass, MD3,5,7 and
- Matthew D Stachler, MD,PhD6,7,*
- 1Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
- 2Inform Diagnostics, Irving, Texas, USA
- 3Department of Molecular Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
- 4R Lash MD, LLC, Southlake, TX, USA
- 5Eli and Edythe L. Broad Institute, Cambridge, Massachusetts, USA
- 6Department of Pathology, University of California San Francisco, San Francisco, CA, USA
- ↵*Corresponding Authors
Mark Redston, Dept of Pathology, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115, mredston{at}partners.org, Matthew D Stachler, Dept of Pathology, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, Matthew.Stachler{at}UCSF.edu
↵7 These authors contributed equally to this work
Author Contributions: Data analysis: MR, MDS, AN; Computational analysis: MDS; Patient selection and clinical data collection: MR, AN, DS, LN; DNA isolation: FGA, AK; Histologic review: MR, AN, RL, MDS; Conceived of study: MR, AN, RL, MDS, AJB; Manuscript preparation: MDS, MR; Manuscript review: MDS, MR, AN, AK, FGA, RL, AJB
Posted October 21, 2020.
Abnormal TP53 predicts risk of progression in patients with Barrett’s esophagus regardless of a diagnosis of dysplasia
